Relypsa Inc. (NASDAQ:RLYP)’s share price traded up 4.8% during mid-day trading on Monday . The stock traded as high as $21.21 and last traded at $21.14, with a volume of 2,443,787 shares traded. The stock had previously closed at $20.17.

Several equities analysts have recently issued reports on the company. BTIG Research reaffirmed a “buy” rating and issued a $45.00 price target on shares of Relypsa in a research report on Saturday, April 9th. Wedbush reaffirmed an “outperform” rating and issued a $52.00 price target on shares of Relypsa in a research report on Saturday, April 9th. Mizuho reaffirmed a “hold” rating on shares of Relypsa in a research report on Sunday, April 17th. Brean Capital reaffirmed a “buy” rating and issued a $26.00 price target on shares of Relypsa in a research report on Sunday, April 17th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $42.00 price target on shares of Relypsa in a research report on Wednesday, May 4th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. Relypsa presently has an average rating of “Buy” and a consensus price target of $34.53.

The stock’s 50 day moving average price is $18.57 and its 200-day moving average price is $17.74. The stock’s market capitalization is $918.20 million.

Relypsa (NASDAQ:RLYP) last posted its quarterly earnings results on Wednesday, May 4th. The company reported ($1.26) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.46) by $0.20. The firm earned $12.40 million during the quarter, compared to analyst estimates of $6.88 million. During the same quarter last year, the business posted ($0.78) earnings per share. Analysts anticipate that Relypsa Inc. will post ($5.91) earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of the company. California Public Employees Retirement System purchased a new position in Relypsa during the fourth quarter worth approximately $3,826,000. Royce & Associates LLC increased its position in Relypsa by 34.6% in the fourth quarter. Royce & Associates LLC now owns 407,700 shares of the company’s stock worth $11,554,000 after buying an additional 104,700 shares during the period. CAM Group Holding A S increased its position in Relypsa by 46.2% in the fourth quarter. CAM Group Holding A S now owns 293,000 shares of the company’s stock worth $8,304,000 after buying an additional 92,640 shares during the period. GAM Holding AG increased its position in Relypsa by 91.5% in the fourth quarter. GAM Holding AG now owns 193,000 shares of the company’s stock worth $5,470,000 after buying an additional 92,200 shares during the period. Finally, Oxford Asset Management purchased a new position in Relypsa during the fourth quarter worth approximately $2,267,000.

Relypsa, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of polymer-based drugs to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patients’ lives and even be life-threatening. The Company’s first drug candidate is Veltassa (patiromer) for oral suspension, or Veltassa, for the treatment of hyperkalemia.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.